Treatment of advanced malignant melanoma with interferon alpha and etretinate.
The combination of recombinant human interferon alpha A 9 MU daily intramuscularly and etretinate 50 mg daily orally was given to 25 patients with progressive advanced, metastatic melanoma. The treatment was well tolerated. Partial responses were seen in three (12%) patients lasting from 2 to 8 months. A further partial response was seen in one of three patients when they were given vindesine and DTIC whilst they continued receiving interferon and etretinate.
Rustin
G J
GJ
Regional Radiotherapy and Oncology Centre, Mount Vernon Hospital, Northwood, Middlesex, U.K.
Dische
S
S
de Garis
S T
ST
Nelstrop
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003606:Dacarbazine / Q000008:administration & dosage; D005050:Etretinate / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy; D014751:Vindesine / Q000008:administration & dosage
D007370:Interferon Type I; D005050:Etretinate; D003606:Dacarbazine; D014751:Vindesine